Audit: QRS - Castor Oil for Health & Longevity

Audit conducted on 20/09/2026 18:16 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked across every populated span: at-a-glance against ER Conclusion (ER lines 508-510), Protocol cells against ER lines 380-394, Time to effect against ER lines 394/443, tiers against the ER benefit and risk headings, gates against ER lines 324-354, monitoring against the ER table (ER lines 469-477) and cadence paragraph (ER line 465), qualitative items against ER lines 481-486. No unsupported claim found.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER hedge is dropped or hardened; the QRS carries no empty-state or certainty-bearing phrasing of its own.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Tier placements and gate severities match the ER exactly; e.g. Digoxin stays an interaction (ER line 326) and is not promoted to a contraindication.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All Contraindications come from the ER avoid-list (ER lines 346-354) and all Key Interactions from the ER interaction bullets (ER lines 324-342); no Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study citations, NCT identifiers or brand names appear anywhere in the QRS; the expert names in the ER protocol bullet (Jennifer Craig, Kazuo Tsubota, ER line 386) are correctly stripped from action_2_sub.
1.6	The QRS does not introduce new attributions.	🟢	No attribution of any kind is introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, mechanism-first register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining readable; tiers and thresholds carry the information without hype.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as evidence and thresholds, not as instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive or clinical-advice construction in the document voice; the footer disclaimer is unmodified template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cells state doses, windows and targets as facts rather than recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun appears anywhere in the QRS.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; the only technical terms are ER section and biomarker labels that items 4.2/4.3 require verbatim.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are bare one-liners, benefit and risk tiers are semicolon-joined headings, and the cadence paragraph is compressed from the ER’s 120-word passage to 84 words.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address anywhere in the sheet.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes a reader weighing the intervention deliberately, with thresholds and monitoring targets supplied.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol cells present four-week regimens and repeat laboratory monitoring without softening the effort involved.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched at the general population; the monitoring table and cadence assume willingness to test and track.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Risk weighting leads with the pregnancy hazard and near-universal cramping, which is the signal that matters for a self-administering optimiser.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route of administration is given formally (“Taken orally”, “oral dose”, “oral laxative”, “Narrow-window oral medications”); no “pill”, “shot”, or “by mouth” phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Verified against the template: “Protocol” (line 445), “Time to effect” (491), “Benefits” (539), “Risk & Side Effects” (604), “Monitoring” (633), “Qualitative Assessment” (779), “Contraindications” (566), “Key Interactions” (582), tier labels in the benefits and risks lists, and “Marker”/”Target”/”Why” (637-639).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Mechanical comparison against [qrs_template]: all 34 template variable names are present; the only additions are the numbered expansions of the repeatable marker_#* and qualitative_item# rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template with span contents blanked shows no change outside the variable regions; the three <span website="..."> elements and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty; every mapped ER section (Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring Protocol) carries content, so no empty-state phrasing is called for.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard oral laxative dose”, action_2_label “Eyelid and dry eye application” and action_3_label “Osteoarthritis regimen” reproduce the ER bold labels at ER lines 380, 386 and 384; all nine marker names reproduce the ER biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is paraphrased or invented; the three Time to effect labels condense the unlabelled clauses of the single ER “Time to effect” bullet (ER line 443), which supplies no bold labels of its own.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji code points in the QRS, against ten in the ER; the ER’s tier emoji and the “⚠️ Conflicted” / “⭕️ Not Central” markers on two benefit headings are all stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: interaction bullets reduced to bare agents plus example lists, benefits and risks reduced to tier headings, contraindications trimmed of glosses, cadence cut to 84 words, at-a-glance to 54. No section is padded or extended.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens at line 2, immediately after <!doctype html> on line 1, and precedes all other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3 and closing “—” at line 13, inside the comment; the “QRS — Metadata” caption on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is enclosed in an HTML comment and no value is echoed by any rendered element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine values are trimmed and unquoted except duration: "00:04", which contains a colon and therefore requires YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: castor_oil_2026-0920-1611_Opus_ER.md, matching the audited source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge at the head of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0920-1810, in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number only; no context-window or edition qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: castor_oil_2026-0920-1611_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: no leading or trailing whitespace and no unnecessary quoting on any key.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Castor Oil for Health & Longevity - Quick Reference Sheet”, matching canonical_topic (ER line 8) with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Castor Oil for Health & Longevity”, entity-encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/20/2026”, the MM/DD/YYYY form of qrs_creation_date 2026-0920-1810.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER’s “Also known as” line (ER line 33) is correctly absent, and there is no badge, version stamp or audit date.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (ER lines 508-510) to mechanism, the two decision-relevant uses, the dominant hazard and the dominant adverse effect.
7.2	[at_a_glance] is no longer than 60 words	🟢	54 words, counted mechanically.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four sentences maps to a distinct Conclusion passage: mechanism (ER line 508), oral and uterine effect with the pregnancy hazard (ER line 508), eyelid effect (ER line 508), cramping and nausea (ER line 510).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; wording stays at the ER Conclusion’s plain-language level (“plant oil”, “fatty acid”, “empties the bowel”, “gritty, inflamed lid conditions”).
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No relative risk, confidence interval or percentage appears; “nearly every full oral dose” is the ER’s own qualitative phrasing, not the pooled RR of 59.92.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items trace to the ER Key Interactions & Contraindications avoid-list (ER lines 346-354).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Nine QRS items against nine ER avoid-list bullets, in ER order, with none added or omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is its own <li> inside the stop_items span (QRS lines 569-577).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No mitigation, rationale or citation is carried through; the only dashes are the en-dash inside “Class III–IV” and the range dash in the eGFR threshold, neither of which introduces a trailing clause. The ER’s “particularly on loop diuretics” tail (ER line 352) is stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The decision-bearing qualifiers are all retained: “before 39 completed weeks”, “stage 4 or worse (filtration rate below 30 mL/min/1.73 m²)”, “New York Heart Association Class III–IV”, “below 3.5 mmol/L”, “under 12 years”. The only parentheticals dropped are the definitional examples at ER lines 349-350, which are none of the categories this item enumerates.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications avoid-list (ER lines 346-354) uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, so the emptiness restriction is not engaged.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Contraindications gate is not empty; it carries nine items (QRS lines 569-577).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items trace to the ER interaction bullets (ER lines 324-342).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten QRS items against ten ER interaction bullets, in ER order; none duplicates a Contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is its own <li> inside the caution_items span (QRS lines 585-594).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity words (“caution”, “monitor”), mechanisms and every “Mitigation:” clause are stripped; no item carries a trailing dash clause.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists are preserved in all seven bullets that carry them; only the lay glosses are dropped (“medications that increase urine output”, “blood thinners that block vitamin K”, “which make the uterus contract”), and “magnesium oxide or citrate” is trimmed to “magnesium”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets (ER lines 324-342) use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, so the emptiness restriction is not engaged.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Key Interactions gate is not empty; it carries ten items (QRS lines 585-594).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets trace to the ER Therapeutic Protocol (ER lines 380-394).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three self-administrable regimens are selected; the bowel-preparation adjunct is correctly passed over as procedural (“directed by the endoscopy service rather than self-administered”, ER line 382) and the pack as the Low-tier use.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol names more than three actionable implementation aspects, so all three action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content; the “Best time of day” and dosing-window detail (ER lines 392, 394) is folded into action_1_sub.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Bowel evacuation, eyelid and tear film, and knee osteoarthritis are taken from the ER “Time to effect” bullet (ER line 443).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High, High, Medium: bowel evacuation and eyelid relief are High-tier benefits (ER lines 156, 162), knee osteoarthritis is Medium (ER line 182); the pack, a Low-tier benefit, is the one dropped.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names four time-to-effect aspects (ER line 443), so all three time sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry ER-derived content, including the resolution window from ER line 394.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER lines 394, 443); the Time to effect row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All four tiers reproduce the ER Expected Benefits headings (ER lines 154-218).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are populated and correctly tiered.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER H4 headings alone; no magnitude line, trial detail or mechanism is carried across.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER benefit headings carry no parentheses, and no parenthetical content from the ER Magnitude lines is imported.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER, so no benefits span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All four tiers reproduce the ER Potential Risks & Side Effects headings (ER lines 240-304).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are populated and correctly tiered.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER H4 headings alone; the Cochrane nausea figures and the 3,000 mg permeability detail stay out.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical frequency, severity grade or study note is carried across.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no risks span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All nine rows and the cadence text derive from the ER Monitoring Protocol & Defining Success section (ER lines 465-477).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	Nine QRS rows against nine ER table rows, with names, ranges and rationales matching; the biomarkers named in the ER prose panel (potassium, sodium, magnesium, bicarbonate, eGFR, tear break-up time) are all in the table.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with an 84-word condensation of the ER cadence paragraph (ER line 465), covering the no-testing case, the baseline trigger conditions, the one-week and six-to-twelve-month repeats, and the ocular schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the qualitative marker list at ER lines 481-486.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Six QRS items against six ER bullets, in ER order, with the trailing explanatory clauses at ER lines 481 and 484 correctly stripped.

Issues 20/09/2026 18:16

Pass rate 100.00%. No issues found.